Journal ArticleDOI
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E. Hynes,Heidi Lane +1 more
TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.Abstract:
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.read more
Citations
More filters
Journal ArticleDOI
EGFR and HER2 signaling in breast cancer brain metastasis.
Sherona Sirkisoon,Richard L. Carpenter,Tadas Rimkus,Lance D. Miller,Linda J. Metheny-Barlow,Hui-Wen Lo +5 more
TL;DR: This review will first provide an overview of the HER2 and EGFR signaling pathways, then the roles that EGFR and HER2 play in breast cancer metastasis to the brain will be discussed, and the preclinical and clinical effects of EGFR- and Her2-targeted therapies on breast Cancer metastasis are summarized.
Journal ArticleDOI
HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes.
Mako Narisawa-Saito,Keisuke Handa,Takashi Yugawa,Shin Ichi Ohno,Masatoshi Fujita,Tohru Kiyono +5 more
TL;DR: Data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes and shows that tumor formation of ErBB2-shRNA introduced SiHa cells were almost abolished.
Journal ArticleDOI
The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility.
K Roovers,Simona Wagner,C J Storbeck,Paul O'Reilly,Vivian Lo,Jason J. Northey,J Chmielecki,William J. Muller,Peter M. Siegel,Luc A. Sabourin +9 more
TL;DR: The role of SLK in chemotaxis downstream of the tyrosine kinase receptor, HER2/ErbB2/Neu, which is frequently overexpressed in human breast cancers, is investigated and an interaction between Neu and SLK signaling in the regulation of cancer cell motility is defined.
Journal ArticleDOI
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung.
Tobias Grob,Ivonne Kannengiesser,Maria C. Tsourlakis,Djordje Atanackovic,Alexandra M. Koenig,Yogesh K. Vashist,Hans Klose,Andreas H. Marx,Susan Koops,Ronald Simon,Jakob R. Izbicki,Carsten Bokemeyer,Guido Sauter,Waldemar Wilczak +13 more
TL;DR: High-level ERBB2 amplification occurs in a small fraction of lung cancers with a strong propensity to high-grade adenocarcinomas, andeterogeneity of amplification may limit the utility of anti-HER2 therapy in some of these tumors.
Journal ArticleDOI
Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Shawn C. Owen,Nish Patel,Jennifer Logie,Guohua Pan,Helena Persson,Jason Moffat,Sachdev S. Sidhu,Molly S. Shoichet +7 more
TL;DR: It is demonstrated the importance of understanding the influence of the antibody-conjugate on cell trafficking for ultimate optimization of treatment selection by utilizing phage-display technology to generate a novel anti-HER2 mAb that binds an epitope of HER2 distinct from that of trastuzumab.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more